A new epoprostenol formulation for the treatment of pulmonary arterial hypertension

American Journal of Health-System Pharmacy

Volumn 69, Issue 16, 2012, Pages 1389-1393

  Fuentes, Amaris ^a   Coralic, Aida ^a   Dawson, Kyle L ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTACYCLIN; TEZOSENTAN;

AGITATION; ANXIETY; BRADYCARDIA; CHILL; CONTINUOUS INFUSION; DIZZINESS; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STABILITY; FLU LIKE SYNDROME; FLUSHING; HEADACHE; HUMAN; HYPOTENSION; INFECTION; JAW PAIN; MYALGIA; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; VOMITING;

EID: 84865983705     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110687     Document Type: Review

References (26)

1. McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009; 53:1573-619.
2. Safdar Z. Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs. Respir Med. 2011; 105:818-27.
3. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004; 351:1425-36.
4. Barst RJ, Gibbs SR, Hossein AG et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54:S78-84.
5. Flolan (epoprostenol) prescribing information. Research Triangle Park, NC: GlaxoSmithKline; 2011.
6. Epoprostenol prescribing information. Irvine, CA: Teva Parenteral Medicine, Inc.; 2008.
7. Rubin LJ, Mendoza J, Hood M et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Ann Intern Med. 1990; 112:485-91. (Pubitemid 20100285)
8. Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996; 334:296-301. (Pubitemid 26033085)
9. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med. 2000; 132:425-34. (Pubitemid 30149039)
10. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999; 99:1858-65. (Pubitemid 29181415)
11. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol. Circulation. 2002; 106:1477-82.
12. Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. J Am Coll Cardiol. 2002; 40:780-8. (Pubitemid 34925627)
13. Thenappan T, Shah SJ, Rich S et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Resp J. 2007; 30:1103-10. (Pubitemid 351194756)
14. Veletri (epoprostenol) prescribing information. San Francisco, CA: Actelion Pharmaceuticals US, Inc.; 2011.
15. Center for Drug Evaluation and Research, Food and Drug Administration. NDA 22-260, epoprostenol for injection, 1.5 mg vial, GeneraMedix Inc. 2008.
16. Augoustides JG, Culp K, Smith S. Rebound pulmonary hypertension and cardiogenic shock after withdrawal of inhaled prostacyclin. Anesthesiology. 2004; 100:1023-5. (Pubitemid 38392596)
17. Augoustides JG. Treatment of rebound pulmonary hypertension: why not sildenafil? Anesthesiology. 2004; 101:1481.
18. The ASHP discussion guide on USP chapter 797 for compounding sterile preparations. www.ashp.org/s-ashp/docs/files/discguide797-2008.pdf (accessed 2012 May 16).
19. Hackman AM, Lackner TE. Pharmacotherapy for idiopathic pulmonary arterial hypertension during the past 25 years. Pharmacotherapy. 2006; 26:68-94. (Pubitemid 43082929)
20. Remodulin (treprostinil) prescribing information. Research Triangle Park, NC: United Therapeutics Corporation; 2012.
21. Simonneau G, Barst RJ, Galie N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002; 165:800-4. (Pubitemid 34229650)
22. McLaughlin VV, Gaine SP, Barst RJ et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003; 41:293-9. (Pubitemid 36135255)
23. Vachiéry JL, Hill N, Zwicke D et al. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest. 2002; 121:1561-5.
24. Red Book Online 2012 [online monograph]. Montvale, NJ: Thompson Reuters (accessed 2012 Feb 13).
25. Actelion Pharmaceuticals Ltd. Marketed products, September 2011. www.actelion. com/documents/corporate/fact-sheet/FS-MarketedProducts.pdf (accessed 2012 May 16).
26. Institute for Safe Medication Practices. ISMP's list of high-alert medications. www.ismp.org/Tools/highalertmedications.pdf (accessed 2012 Apr 30).